Accanito develops oncology therapeutics that target mitochondrial function in cancer cells, aiming to disrupt tumor‑specific energy metabolism while sparing healthy tissue. Its lead asset, GAM‑05, is a first‑in‑class mitochondria‑targeted HSP inhibitor that selectively accumulates in tumor mitochondria, blocks energy pathways and triggers irreversible cancer cell death, showing strong preclinical efficacy. The company focuses on mechanism‑driven drug development to overcome resistance and improve patient survival across multiple cancer types.
Funding
Funding not disclosed
Founders
Product
Problem
Current cancer therapies often rely on mechanisms that affect both tumor and healthy cells, leading to limited efficacy, resistance development, and significant side effects. Many patients with advanced or treatment‑resistant cancers lack targeted options that can overcome metabolic adaptations of tumor cells.
Solution
Accanito is developing a first‑in‑class oncology platform centered on GAM‑05, a mitochondria‑targeted heat‑shock protein (HSP) inhibitor that selectively accumulates in tumor mitochondria. By disrupting tumor‑specific energy metabolism, GAM‑05 triggers irreversible apoptosis in cancer cells while sparing normal tissue. The approach leverages a differentiated mechanism to address resistance pathways and improve overall survival outcomes. Preclinical studies demonstrate strong efficacy and tumor‑selective uptake, positioning the platform as a precision therapy for unmet oncology indications.
Target Audience
Primary customers are pharmaceutical partners and oncology research programs seeking novel, mechanism‑driven therapies for patients with advanced, treatment‑resistant cancers.
Features
- First‑in‑class HSP inhibitor engineered for mitochondrial localization in cancer cells
- Tumor‑selective accumulation reduces off‑target toxicity to healthy tissues
- Disruption of mitochondrial energy pathways induces irreversible cell death
- Mechanism designed to overcome common resistance mechanisms in solid tumors
- Scalable drug development platform supporting multiple oncology indications